FDA Grants Full Approval to Pfizer COVID-19 Vaccine
Monday, August 23, 2021
On Monday morning the Food and Drug Administration (FDA) granted full approval to Pfizer and BioNTech Covid-19 vaccine – becoming the first vaccine in the U.S. to meet the full approval standard.
The final approval is expected to spark governments and employers to require employees to be vaccinated.
GET THE LATEST BREAKING NEWS HERE -- SIGN UP FOR GOLOCAL FREE DAILY EBLAST
FDA said in its statement:
“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” said Acting FDA Commissioner Janet Woodcock, M.D. “While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”
Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA in individuals 16 years of age and older, and the authorization was expanded to include those 12 through 15 years of age on May 10, 2021. EUAs can be used by the FDA during public health emergencies to provide access to medical products that may be effective in preventing, diagnosing, or treating a disease, provided that the FDA determines that the known and potential benefits of a product, when used to prevent, diagnose, or treat the disease, outweigh the known and potential risks of the product.
FDA-approved vaccines undergo the agency’s standard process for reviewing the quality, safety and effectiveness of medical products. For all vaccines, the FDA evaluates data and information included in the manufacturer’s submission of a biologics license application (BLA). A BLA is a comprehensive document that is submitted to the agency providing very specific requirements. For Comirnaty, the BLA builds on the extensive data and information previously submitted that supported the EUA, such as preclinical and clinical data and information, as well as details of the manufacturing process, vaccine testing results to ensure vaccine quality, and inspections of the sites where the vaccine is made. The agency conducts its own analyses of the information in the BLA to make sure the vaccine is safe and effective and meets the FDA’s standards for approval.
Related Articles
- Pfizer Says Americans Need COVID Vaccine Booster After 6 Months, CDC and FDA Dispute Claim
- FDA Authorizes Pfizer’s Coronavirus Vaccine for Emergency Use
- CVS Pharmacy Suspends Sale of Zantac Products—and More—Due to FDA Investigation
- Some E-Cigarette Users Are Having Seizures, Reports FDA
- FDA Authorizes Moderna Coronavirus Vaccine for Emergency Use
- Johnson & Johnson Submits Application to FDA for Vaccine Approval
- UPDATED: FDA Gives Approval to Biogen’s Alzheimer’s Drug Aducanumab Which Has Deep RI Roots
- CDC and FDA Green Light Use of Johnson & Johnson and in RI There Is a Workaround
- FDA Finds Johnson & Johnson Single Dose COVID Vaccine Safe and Effective
- FDA and CDC “Pause” Johnson & Johnson Vaccine
